Oncothyreon raises $40M for cancer work

Seattle's Oncothyreon has priced a public offering of 10 million shares of its stock at $4 per share in order to raise $37.4 million after  deducting the underwriters' discounts and other expenses. Underwriters have a 30-day option to purchase up to an additional 15 percent of the shares, which could garner up to $6 million more in funding.

The developer plans to use the funding to finance two development projects. PX-866, a PI-3 Pan-isoform irreversible Kinase inhibitor, is in early- and mid-stage trials for a variety of cancers, and ONT-10, a follow-on vaccine to Stimuvax. The Phase III Stimuvax is a vaccine for patients with non-small cell lung cancer that Oncothyreon is developing with EMD Serono. Early trials of ONT-10 are expected to begin later this year.

- here's Oncothyreon's release

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.